Anticaries Potential of a Sodium Monofluorophosphate Dentifrice Containing Calcium Sodium Phosphosilicate: Exploratory in situ Randomized Trial by Parkinson, C. R. et al.
Anticaries Potential of a Sodium Monofluorophosphate Dentifrice Containing Calcium Sodium 
Phosphosilicate: Exploratory In Situ Randomised Trial 
Short title: Anticaries Potential of a CSPS Dentifrice 
C.R. Parkinsona, M. Siddiqia, S. Masona, F. Lippertb, A.T. Harab, D.T. Zerob 
aGSK Consumer Healthcare, Weybridge, UK; bOral Health Research Institute, Indiana University 
School of Dentistry, Indianapolis, IN, USA 
Corresponding author: Charles Parkinson, GSK Consumer Healthcare, St George’s Avenue, 
Weybridge, Surrey, KT1 0DE. Email: charles.x.parkinson@gsk.com. Tel: 07920 568 718 
Declaration of interests 
C.R.P., M.S., and S.M. are employed by GSK Consumer Healthcare. D.T.Z., A.T.H., and F.L. have 
received compensation from GSK Consumer Healthcare as consultants. This study was supported by 
GSK Consumer Healthcare. 
Key Words 
Dentifrice, NovaMin®, Calcium sodium phosphosilicate (CSPS), Fluoride, Caries, In situ model 
___________________________________________________________________
This is the author's manuscript of the article published in final edited form as:
Parkinson, C. R., Siddiqi, M., Mason, S., Lippert, F., Hara, A. T., & Zero, D. T. (2017). Anticaries Potential of a 
Sodium Monofluorophosphate Dentifrice Containing Calcium Sodium Phosphosilicate: Exploratory in situ 
Randomized Trial. Caries research, 51(2), 170. https://doi.org/10.1159/000453622
2 
 
Abstract 
Calcium sodium phosphosilicate (CSPS) is a bioactive glass material that alleviates dentin 
hypersensitivity and is postulated to confer remineralization of caries lesions. This single-centre, 
randomized, single (investigator) blind, placebo-controlled, crossover, in situ study explored whether 
the addition of 5% CSPS to a nonaqueous, fluoride (F) as sodium monofluorophosphate (SMFP)-
containing dentifrice affects its cariostatic ability. Seventy-seven subjects wore four gauze-covered 
enamel specimens with pre-formed lesions (two surface-softened and two subsurface) placed buccally 
on their mandibular bilateral dentures for up to 4 weeks. Subjects brushed twice daily with one of the 
five study dentifrices: 927ppm F/5% CSPS, 927ppm F/0% CSPS, 250ppm F/0% CSPS, 0ppm F/5% 
CSPS, or 0ppm F/0% CSPS. Specimens were retrieved after either 21 (surface-softened lesions; 
analyzed by Knoop surface microhardness [SMH]) or 28 days (subsurface lesions; analyzed by 
transverse microradiography). Enamel fluoride uptake (EFU) was determined on all specimens using 
a microbiopsy technique. Concentrations of fluoride and calcium in gauze-retrieved plaque were also 
evaluated. Higher dentifrice fluoride concentrations led to greater remineralization and fluoridation of 
both lesion types and increased plaque fluoride concentrations. CSPS did not improve the cariostatic 
properties of SMFP: there were no statistically significant differences between 927ppm F/5% CSPS 
and 927ppm F/0% CSPS in percent SMH recovery (p=0.6788), change in integrated mineral loss 
(p=0.5908) and lesion depth (p=0.6622). Likewise, 0ppm F/5% CSPS did not provide any benefits in 
comparison to 0ppm F/0% CSPS. In conclusion, CSPS does not negatively impact nor does it improve 
the ability of a SMFP dentifrice to affect remineralization of caries lesions.  
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Introduction 
It is now generally believed that fluoride exerts its anti-caries effects predominantly via relatively 
small, but protracted, increases in concentration in plaque and saliva [Featherstone, 2008; ten Cate, 
2013].To achieve the desired remineralization and anticaries effects of fluoride the dentition should be 
exposed to elevated levels of fluoride on a continuous basis. The fluoride found within saliva is 
primarily derived from fluoride-containing dentifrices and although levels of free fluoride initially 
decrease rapidly after the immediate post-brushing peak, the fluoride clearance profile is believed 
biphasic with a much slower second phase so that somewhat raised fluoride levels may be found even 
several hours after brushing [Duckworth et al., 1992]. The net result is that regular use of a fluoridated 
dentifrice leads to an overall increase in resting levels of fluoride in saliva [Duckworth et al., 1992; 
Edgar et al., 1992].   However, the availability of calcium and phosphate ions has been reported to be 
a limiting factor in the retention and prolonged release of fluoride in the oral cavity, and for the net 
remineralisation of enamel [Cochrane, 2010].   
 
Calcium sodium phosphosilicate (CSPS), a bioactive glass material, was originally developed for the 
alleviation of dentin hypersensitivity [Gendreau et al., 2011], but may also have potential usefulness 
for remineralization of caries lesions [Wefel, 2009; Burwell et al., 2009]. The proposed mechanism of 
action is based on the ability of CSPS to release physiologically relevant levels of calcium and 
phosphate ions into saliva [Grootveld, 2009] and provide suitable conditions to facilitate the 
formation of a hydroxycarbonate apatite compound over the surface of dentin [Burwell et al., 2009; 
Wefel, 2009]. A number of previous studies have tested whether CSPS interacts positively with 
fluoride in combination dentifrices. Burwell et al. [2009] conducted a series of in vitro studies to 
investigate the demineralization-prevention and remineralization-enhancement effects of CSPS 
dentifrices with and without fluoride and observed that these treatments markedly re-hardened enamel 
specimens. The addition of CSPS as a source of calcium may have been responsible for enhancing the 
remineralization potential of fluoride in that experimental model. Meanwhile, in a similar preliminary 
in vitro study, Gjorgievska et al. [2010] reported increased remineralization of enamel with a CSPS-
containing dentifrice, as assessed by energy dispersive X-ray spectroscopy analysis, and concluded 
that this bioactive glass material has potential to remineralize enamel. 
 
This proof-of-principle clinical trial was conducted to elucidate potential interactions of CSPS on the 
efficacy of a SMFP-containing dentifrice (927 ppm fluoride [F]) to promote remineralization and 
prevent further demineralization of two lesion types designed to model the earlier and later stages of 
the caries process—surface-softened lesions and subsurface caries lesions, respectively—using an 
established in situ caries model [Zero et al., 2004]. Enamel remineralization was assessed by surface 
microhardness (SMH) for the surface lesions and by transverse microradiography (TMR) for the 
subsurface lesions. In addition, post-treatment concentrations of fluoride and calcium in the enamel 
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specimens and plaque from the gauze covering them were evaluated. The 927 ppm F/5% CSPS 
dentifrice was compared to a 0 ppm F dentifrice with 5% CSPS, and 927 ppm F, 250 ppm F and 0 
ppm F dentifrices without CSPS.  
 
Materials and Methods 
This was a single centre, randomized, investigator-blind, placebo-controlled, five-treatment, five-
period, crossover, in situ study conducted in healthy subjects who provided written informed consent 
prior to screening. The study was conducted according to the Declaration of Helsinki. This study was 
funded by GSK Consumer Healthcare and was conducted at the Oral Health Research Institute 
(OHRI), Indiana University School of Dentistry, Indianapolis, IN, USA with the protocol approved by 
the IUPUI Institutional Review Board (#1006-65).  First enrolment was in July 2010.  There were two 
amendments to the protocol, regarding brushing regimen instructions, specimen randomization, 
microdrill depth, and wording of analysis instructions. 
 
Study Population 
Main inclusion criteria were healthy subjects aged 18–80 years who wore a removable bilateral 
mandibular partial denture capable of housing specimens and had normal reference range 
unstimulated and stimulated (by chewing unflavored gum base) salivary flow (pooled saliva ≥0.2 and 
≥0.8 mL/minute, respectively). Subjects with active caries lesions or periodontal disease were 
excluded. 
 
Test and Reference Products and Doses 
The following dentifrices were evaluated over a 28-day brushing regimen: 
• Experimental: 927 ppm F as SMFP + 5% w/w CSPS (927 ppm F/5% CSPS group) 
• Fluoride control: 927 ppm F as SMFP + 0% w/w CSPS (927 ppm F/0% CSPS group) 
• Fluoride dose-response control: 250 ppm F as SMFP + 0% w/w CSPS (250 ppm F/0% CSPS 
group) 
• Reference control: 0 ppm F + 5% w/w CSPS (SensiShieldTM; Periproducts Ltd, UK) (0 ppm 
F/5% CSPS group) 
• Placebo dose-response control: 0 ppm F + 0% w/w CSPS (0 ppm F/0% CSPS group) 
 
With the exception of the Reference control, all the dentifrices were ‘formulation matched’, i.e., the 
formulations contained the same levels and type of formulation excipients, and none contained any 
other source of calcium or phosphate beyond CSPS. The Reference control differed from the other 
formulations with respect to minor differences in the level and type of abrasive silica.  The difference 
in level and grade of silica between the Reference control and the other formulations would not be 
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expected to impact on the usability of the dentifrice or result in detectable differences in taste by the 
subject. To maintain investigatorblind masking, all study toothpastes were supplied in plain white 
tubes.  
 
Clinical Procedures 
At screening, subjects were given an oral soft tissue (OST) and oral hard tissue (OHT) examination 
and their unstimulated and stimulated salivary flow rates were determined. Subjects then entered a ≥6-
day washout period during which they followed their usual oral and dental hygiene practices for ≥4 
days then returned to the study site for a dental prophylaxis. Thereafter, subjects were instructed to 
use only the study washout toothpaste (0 ppm F) and toothbrush for 2–3 days before the start of each 
treatment period. Subjects were provided with a new toothbrush for each new treatment period. Order 
of treatment was randomly allocated for each subject according to a sequence determined by the 
Biostatistics Department of GSK Consumer Healthcare. 
 
During each of five 28 day test periods, subjects wore modified bilateral mandibular partial dentures 
holding four partially demineralized bovine enamel specimens (two with surface-softened and two 
with subsurface lesions, see below) continuously for 24 hours/day including at mealtimes and while 
brushing. Subjects could remove the partial denture briefly to rinse their mouth with tap water after 
eating and to clean the denture. Use of any other dental hygiene products or practices except 
interdental cleaners such as floss was disallowed during the study period. 
 
The first brushing regimen of each treatment period was completed on site under supervision, 
following which subjects were instructed to brush their natural teeth only with a full ribbon of study 
toothpaste at home for 1 timed minute twice daily (morning and at bedtime) for 28 days, taking care 
not to brush the enamel specimens. The two specimens with surface-softened lesions were removed at 
the end of 21 days, the two with subsurface lesions were removed at the end of 28 days, having 
brushed for the final time the night before specimen removal .  Compliance with brushing procedures 
was recorded in subject diaries, as were any new, or changes in existing, medical conditions, 
medications, or treatments. All subjects received a professional fluoride treatment at the end of the 
study.  
 
Model Caries Lesions 
Specimens were obtained from bovine incisors, polished to create flat surfaces as described elsewhere 
[Zero et al., 1990]. Surface-softened lesions were created according to a modified method of White 
[1987]. Enamel specimens were immersed in 40 mL acid buffer (0.05 M lactic acid) 50% saturated 
with respect to hydroxyapatite with 0.2% (wt/vol) Carbopol® 907 (BF Goodrich, Cleveland, OH, 
USA) at 37°C for 24 hours. Subsurface lesions were prepared by demineralizing enamel specimens in 
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8% methylcellulose gel (Sigma M0387, aqueous, 1,500 cP, 63 kDa) covered with an equal mass of 
0.1 M lactic acid, adjusted to pH 4.6, at 37°C for 7 days. Lesion quality was deemed acceptable if 
lesioned areas displayed uniform opacity and surface shine on exposure to overhead light. Following 
preparation, specimens were stored in a moist environment to prevent dehydration; they were 
sterilized by ethylene oxide gas prior to insertion into dentures. 
A total of four partially demineralized enamel specimens were placed in the buccal flange area on 
either side of the subject’s bilateral partial denture: two 4 × 4 mm enamel specimens with surface-
softened lesions and two 4 × 5 mm enamel specimens with subsurface lesions were placed in the 
buccal flange area on either side of subjects’ bilateral partial denture. Pairs of specimens were 
wrapped together in Polyester Knit Fabric (Item P01628; Bard Peripheral Vascular, Tempe, AZ, 
USA) to facilitate plaque growth [Koulourides et al., 1974; Featherstone and Zero, 1992] and were 
mounted flush with the denture surface. 
Surface Microhardness 
SMH was determined using the Knoop hardness test [Knoop et al. 1939] for specimens with surface-
softened lesions using a Wilson 2100 Hardness Tester (Norwood, MA, USA) with indentation length 
measured using Wilson-Wolpert PC-based Video Filar image analysis software (version 3.5.032) 
(Illinois Tool Works Inc., Glenview, IL, US). Prior to demineralization, five baseline indentations 
spaced 100 µm apart were created with a Knoop diamond under a 50 g load. Average indentation 
length of 43 ±3 µm were deemed acceptable for specimen inclusion. After demineralization, five 
further indentations were created 100 µm to the left of the baseline indentations and SMH was again 
determined. Only specimens with indentation lengths 120 ±20 µm were deemed suitable for use. After 
21 days’ intraoral treatment, five further indentations were made in each specimen to the right of the 
baseline indentations. The extent of remineralization was calculated as a function of percent reduction 
of indentation length after versus before in situ intraoral exposure (percent SMH recovery) [SMHR]) 
[Gelhard et al. 1979]. 
Transverse Microradiography (TMR) 
For specimens with subsurface lesions, changes in integrated mineral loss (ΔM=∆Zbase-∆Zpost), lesion 
depth (ΔL=Lpost-Lbase), and maximum mineral density of the lesion surface zone (ΔSZmax=SZmax,post-
SZmax,base) before and after treatment were analyzed by TMR. Following lesion creation and after 28 
days’ treatment, a section approximately 100 µm thick was cut from across the lesion window and 
sound enamel areas using a Silverstone-Taylor Hard Tissue Microtome (Scientific Fabrications, 
Lafayette, CO, USA), polished, mounted on plates, and x-rayed at 20 kV and 30 mA at a distance of 
42 cm for 65 minutes. Micrographs were examined by Zeiss EOM microscope using TMR software 
v.3.0.0.11 (Inspektor Research Systems BV, Amsterdam, The Netherlands).
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Enamel Fluoride Uptake and Enamel Calcium Uptake 
Fluoride and calcium content of partially demineralized enamel specimens were quantified by 
microdrill enamel biopsy technique [Sakkab et al., 1984]. Briefly, enamel specimens were drilled 
through the entire lesion in a static-controlled atmosphere to prevent loss of powder due to charging 
effects (surface-softened lesions, four cores per specimen, 100 µm in depth; subsurface lesions, two 
cores per specimen each 200 µm in depth). Pooled enamel powder was dissolved in 40 µL 0.5 M 
HClO4. Half this solution was transferred to tubes containing 1.0 mL LaCl3 and 3.98 mL deonized 
water and subjected to atomic absorption analysis for calcium content (expressed per unit area enamel 
cores; µg Ca/cm2) by Perkin Elmer AAnalyst 200 (Waltham, MA, USA). To the remainder of the 
solution was added 40 µL citrate/EDTA buffer and 40 µL deionized water; fluoride content was 
analyzed by fluoride-specific electrode and pH/ion meter and expressed as µg F/cm2. 
 
Enamel Gauze Plaque 
Plaque fluid extracted from gauze strips enclosing enamel samples was analyzed for fluoride and 
calcium content [Martinez-Mier et al., 2010]. Plaque removed from the gauze was placed in an 
ultrasonic bath in 200 µL deionized water to create a homogenous sample. For plaque calcium content 
analysis, 100 µL of the sample was mixed with 900 µL deionized water, 200 µL of 0.01 M NaOH and 
100 µL double strength Arsenazo III. Calcium content was obtained by comparing absorbance 
readings, measured using a spectrophotometer, of calcium standard solutions. For plaque fluoride 
content, 100 µL of the sample was mixed with 500 µL of deionized water then fluoride was recovered 
in a 0.05 N NaOH trap solution using a microdiffusion technique [Taves, 1968; Martinez-Mier et al., 
2004]. Fluoride content was measured by comparison of the millivolt reading of the sample to 
standard curves. 
 
Safety 
Safety was monitored in terms of adverse events (AEs). 
 
Statistical Analysis 
The study aimed to enroll 80 subjects with the intention that approximately 60 subjects would 
complete the entire crossover study design and provide data for efficacy analysis. With 60 evaluable, 
completing subjects the study was calculated to have 90% power at the 5% significance level, using 
two-sided testing, to detect a mean treatment difference for SMHR of approximately 7.6% assuming a 
within-subject standard deviation of approximately 12.6%. 
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Safety was analyzed in the Safety population defined as all subjects randomized who received at least 
one administration of study product. The intent-to-treat (ITT) population was additionally all subjects 
who provided data for at least one post-baseline efficacy assessment. Efficacy was analyzed in the per 
protocol (PP) population defined as subjects in the ITT population who had no major protocol 
violations. 
 
A crossover design was used to eliminate between-subject variability from treatment comparisons, 
each subject acting as their own control. All specimens were analyzed, however for subjects who did 
not complete the study; inter-individual differences may not be fully eliminated and may act to 
decrease the power of the statistical tests for treatment comparisons.   For the efficacy parameters 
SMHR, fluoride or calcium content in enamel, and fluoride or calcium levels in plaque, between 
treatment analyses were performed using a mixed-model analysis of variance (ANOVA) suitable for 
crossover studies. The model included a random effect for subject and fixed effects for study period 
and treatment. For the efficacy parameters, change in mineral content (ΔM), change in lesion depth 
(ΔL), and change in maximal surface mineralization (ΔSZmax), treatment comparisons were performed 
using a mixed model analysis of covariance (ANCOVA) model. The model included a random effect 
for subject and fixed effects for study period and treatment. It also included the corresponding 
baseline measurement as a covariate. All pairwise treatment comparisons were performed using two-
sided testing at the 5% significance level. No adjustment for multiple comparisons was employed as 
the primary comparison had been defined. The assumptions of normality and homogeneity of variance 
were investigated. Violations of these assumptions were observed for the variables ‘fluoride content 
of plaque’ and ‘calcium content of plaque’ at both days 21 and 28. These violations were overcome 
using the log (base 10) transformation.  
 
Results 
Study Population 
Of 92 subjects screened, 77 subjects (57.1% female; mean age 64.51 [range 30.0–80.0] years) were 
enrolled and randomized between 21 July 2010 and 17 February 2011. Fifty-one subjects (66.2%) 
completed the study (Figure 1). 
 
Specimens Analyzed 
For the surface-softened lesions (removed after 21 days) all specimens were analyzed.  For the sub-
surface lesions (removed after 28 days), 21 samples could not be analyzed for reasons including 
accidental removal on day 21, lost by subject, or subject dropped out of study prior to day 28.  
  
 
Efficacy 
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Efficacy results for specimens bearing surface-softened lesions are presented in Table 1 (indentation 
length data [mean±SD]: sound enamel = 43.2 ± 0.8 µm; lesion baseline = 116.9 ± 9.3 µm). In terms of 
SMHR, no significant difference was observed following 21 days’ treatment between 927 ppm F/5% 
CSPS and 927 ppm F/0% CSPS, the primary efficacy comparison. Both treatments containing 927 
ppm F elicited significantly greater SMHR than those with 250 ppm F/0% CSPS (p=0.0004 for 
927/5% CSPS; p=0.0001 for 927/0% CSPS), 0 ppm F/5% CSPS (p<.0001 for both) and 0 ppm F/0% 
CSPS (p=0.0002 for 927/5% CSPS; p<.0001 for 927/0% CSPS). All other treatment comparisons for 
SMHR were nonsignificant. 
 
In subsurface lesions (Table 2; lesion baseline data [mean±SD]: ∆Zbase = 2533±236 vol%min×µm; 
Lbase = 75.3±9.6 µm; SZmax,base = 38.6±6.2 vol%min), after 28 days, while changes in mineral content 
(ΔM) and lesion depth (ΔL) were not significantly different between the two 927 ppm F dentifrices, 
both parameters were statistically significantly different in favor of the 927 ppm F dentifrices when 
either were compared to those containing 0 ppm F, regardless of CSPS content (ΔM: all p<.0001; ΔL: 
all p<0.02). The 927 ppm F/5% CSPS was also significantly different, in its favor, than the 250 ppm 
F/0% CSPS dentifrice (ΔM: p=0.0389; ΔL: p=0.0433). ΔSZmax was significantly higher for 927 ppm 
F/5% CSPS treatment compared with 927 ppm F/0% CSPS (p=0.0114), 0 ppm F/5% CSPS 
(p=0.0007), and 0 ppm F/0% CSPS (p=0.0370) with no other significant between-treatment 
differences. 
Figure 2 shows mean mineral distribution profiles of subsurface lesions for all post-treatment groups 
and after initial demineralization (lesion baseline). Mineral gain in the lesion body can be observed 
for all lesions at the expense of mineral beyond the original lesion. Differences between treatment 
groups were minimal and largely confined to the extent of secondary mineral loss. 
 
Pairwise treatment comparisons of fluoride content of enamel specimens showed no significant 
differences between the two 927 ppm F dentifrices or between the two 0 ppm dentifrices following 
brushing for 21 (surface-softened lesions) or 28 days (subsurface lesions) whereas there were 
statistically significant differences (all p<.0001) between all higher- versus lower-concentration 
SMFP formulations, regardless of CSPS content, at both time-points, favoring the higher 
concentration formulations for all comparisons. 
 
Pairwise treatment comparisons of calcium content of enamel specimens showed no significant 
difference between the two 927 ppm F dentifrices or between the two 0 ppm dentifrices for either 
model lesion type. Treatment with 927 ppm F/5% CSPS was associated with significantly higher 
calcium content than all treatments with lower SMFP content for surface-softened lesions (all p<0.05) 
and the two treatments with 0 ppm F for subsurface lesions (both p<0.01). There were no other 
significant between-treatment differences for surface-softened lesions. For subsurface lesions, the 
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only other statistically significant difference was between 250 ppm F/0% CSPS and 0 ppm F/0% 
CSPS in favor of the former (p=0.0382). 
 
There was no difference in levels of fluoride in plaque from specimen gauze for surface-softened 
lesions. For subsurface lesions there was a statistically significantly higher level of fluoride in the 927 
ppm F/5% CSPS dentifrice group compared to 927 ppm F/0% CSPS (p=0.0393). Treatment with 927 
ppm F with and without 5% CSPS was associated with statistically significantly higher fluoride 
content of enamel gauze plaque compared with most of the lower-dose SMFP formulations for both 
lesion types (all p<0.05), with the sole exception of the comparison between 927 ppm F/0% CSPS and 
250 ppm F/0% CSPS dentifrice in subsurface lesions. No significant difference of gauze plaque 
calcium concentration was observed between any groups for either lesion type. 
 
Safety 
There were a total of 115 treatment-emergent AEs (TEAEs) reported for 52 subjects (67.5%); TEAEs 
arising in each group are summarized in Table 3. Among these, 54 were oral TEAEs reported in 30 
(39.0%) subjects. Five of the TEAEs were deemed treatment-related, all classified as mild: two 
reports of oral mucosal exfoliation, one in each of the 0 ppm F groups; two reports by one subject of 
stomatitis in the 0 ppm F/5% CSPS group and one report of dysgeusia by one subject in the 0 ppm 
F/0% CSPS group. There were six serious AEs (SAEs) observed for five subjects (one case each of 
pneumonia, large intestine perforation, glioblastoma multiforme, and coronary artery disease and two 
of unstable angina); none of these SAEs was considered related to study treatment and none led to 
study discontinuation. 
 
Discussion 
It is informative to study the effects of dentifrice in both surface-softened and subsurface lesions as a 
sensitive experimental model of the caries process [Zero, 1995]. While surface-softened lesions 
provide insight into the efficacy of anticaries agents during the early stages of caries, surface 
remineralization of softened enamel lesions may obscure additional mineral loss and/or inhibit deeper 
mineral deposition beyond the surface layer [Mukai et al., 2001; Lynch et al., 2007; Lynch and Smith, 
2012],.The kinetics of enamel demineralization are thought to be surface controlled with a more or 
less intact (reformed) surface zone being the rate-limiting factor in further pore reduction of the 
underlying subsurface lesion [Robinson et al., 2000]. Mineral redeposition on the caries lesion surface 
may derive from material dissolved from deeper layers as well as from plaque fluid that re-
precipitates in this region and thereby stabilizes the enamel defect. Fluoride is particularly important 
in this process because it facilitates redeposition and produces a less acid-soluble mineral [Robinson 
et al., 2000].  
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In this study, treatment comparisons were evaluated in the context of a positive fluoride dose 
response, indicative of model validation [Proskin et al., 1992]. For SMHR, EFU and plaque fluoride, 
significant differences were observed between the 927 ppm F/0% CSPS and 250 ppm F/0% CSPS 
dentifrices, in favor of the former. However, for the other efficacy measures, primarily for the 
subsurface lesions, no significant differences were observed between high and low fluoride treatment 
groups. Consequently, only limited conclusions can be drawn from differences in these efficacy 
variables, e.g., while ΔSZmax was statistically significantly higher for 927 ppm F/5% CSPS treatment 
compared with 927 ppm F/0% CSPS (p=0.0114), in the absence of any fluoride dose response this 
observation is not considered clinically significant.  
 
The differential behavior of the surface-softened and subsurface lesions was an interesting finding of 
the present study. Assuming the longer intra-oral exposure of the subsurface lesions was not crucial 
and that SMH measurements correspond to mineral content [Lippert and Lynch, 2014] and are 
therefore comparable to the TMR observations on subsurface lesions, it is striking that surface-
softened lesions remineralized whereas subsurface lesions demineralized further. These observations 
are, at least in principle, in disagreement with the present knowledge about the importance of baseline 
mineral loss of lesions on subsequent in situ de- and remineralization [Strang et al., 1987; Mellberg et 
al., 1992]. One explanation for the present findings may lie in the fact that lesions were not 
comparable in that the surface-softened lesions exhibited a different mineral distribution than the 
subsurface lesions (for comparison, see Lippert and Lynch, 2014 and Lippert et al., 2013). 
Furthermore, surface layers of both lesion types represent different stages of lesion maturation, a 
lesion formed over 7 days will present a more defined (but not necessarily more mineralized) surface 
layer than one that was formed during 24 hours of demineralization. As surface layer formation is a 
dynamic process, the extended demineralization period will not only affect lesion size but also lesion 
surface properties that in turn affect its reactivity, porosity and ability to allow in- and outflow of ions.  
 
Within the limitations of this study, the present results indicate that addition of 5% CSPS to SMFP 
dentifrice neither promotes nor inhibits the ability of fluoride to remineralize enamel. Likewise, it 
appears 5% CSPS does not offer any benefits in its own right as indicated by results obtained on 
fluoride-free formulations. A recent study on dentin mineralization [Jones et al., 2015], combined 
with clinical evidence on the relief from dentin hypersensitivity studies [Gendreau et al., 2011], would 
suggest CSPS’s activity is restricted to dentin and perhaps only to plaque-free surfaces. CSPS has 
been shown to bind to collagen in dentine [Efflandt, 2002] and precipitate hydroxyapatite-like 
material onto dentin surfaces [Burwell et al., 2009; Wefel, 2009].  The absence of collagen binding 
sites on the enamel surface may preclude retention of CSPS to enamel; however, further studies on 
plaque free enamel surfaces would be required to support this. The results from this study also 
indicate that CSPS is poorly retained in plaque.  No enhancement of calcium in plaque for the CSPS 
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treatment groups relative to the controls was observed..  Poor retention of CSPS to enamel or plaque 
surfaces may compromise the ability of CSPS to remineralize caries lesions.  
 
In conclusion, the present in situ caries study found no statistically significant difference in SMHR 
between the 927 ppm F dentifrices with or without 5% CSPS. These results suggest that the addition 
of CSPS to a SMFP-containing dentifrice does not negatively or positively impact the ability of 
fluoride to effect mineralization of surface-softened and subsurface caries lesions. All test dentifrices 
were generally well tolerated.  
 
Acknowledgments 
This study was funded by GSK Consumer Healthcare. CP, MS, and SM contributed to the design, 
conduct, and reporting of the present research. DTZ, ATH, EAMM, FL, and SAK were involved in 
the conduct of the study. All authors had access to the final study report, made contributions to the 
development of the manuscript, had final responsibility for the decision to submit, and approved the 
version submitted. The authors would like to thank Dr Eleanor Roberts of Beeline Science 
Communications, Ltd, funded by GSK Consumer Healthcare, for assistance in the preparation of this 
manuscript.   
13 
 
References 
 
Burwell AK, Litkowski LJ, Greenspan DC: Calcium sodium phosphosilicate (NovaMin®): 
remineralization potential. Adv Dent Res 2009;21:35–39. 
 
Duckworth RM, Morgan SN, Ingram GS, Page DJ: Oral fluid reservoirs and their relationship to 
anticaries efficacy, in: Embery G, Rolla G (eds): Clinical and Biological Aspects of Dentifrices. 
Oxford, Oxford University Press; 1992, pp 91–104. 
 
Edgar WM, Ingram GS, Morgan SN: Fluoride in saliva and plaque in relation to fluoride in drinking 
water and in dentifrice. In: Embery G, Rolla G (eds): Clinical and Biological Aspects of Dentifrices. 
Oxford, Oxford University Press; 1992, pp 157–163. 
 
Efflandt SE, Magne P, Douglas WH, Francis LF: Interaction between bioactive glasses and human 
dentin. J Mater Sci Mater Med 2002;26:557–565.  
 
Featherstone JDB, Zero DT: An in situ model for simultaneous assessment of inhibition of 
demineralization and enhancement of remineralization. J Dent Res 1992;71(Spec Iss):804–810. 
 
Gelhard TBFM, ten Cate JM, Arends J: Rehardening of artificial enamel lesions in vivo. Caries Res 
1979;13:80–83. 
 
Gendreau L, Barlow AP, Mason SC: Overview of the clinical evidence for the use of NovaMin in 
providing relief from the pain of dentin hypersensitivity. J Clin Dent 2011;22:90–95. 
 
Gjorgievska ES, Nicholson JW: A preliminary study of enamel remineralization by dentifrices based 
on Recalden (CPP-ACP) and Novamin (calcium-sodium-phosphosilicate). Acta Odontol Latinoam 
2010;23:234–239. 
 
Grootveld M, Silwood CJL, Winter WT:  High-resolution 1H NMR investigations of the capacity of 
dentifrices containing a “smart” bioactive glass to influence the metabolic profile of and deliver 
calcium ions to human saliva. J. Biomedical Materials Research 2009, 91(1), 88-101 
 
Jones SB, Parkinson CR, Jeffery P, Davies M, Macdonald EL, Seong J, West NX: A randomised 
clinical trial investigating calcium sodium phosphosilicate as a dentine mineralising agent in the oral 
environment. J Dent 2015;43:757–764 
 
14 
 
Knoop F, Peters CG, and Emerson WB: A Sensitive Pyramidal-Diamond Tool for Indentation 
Measurements. Journal of Research of the National Bureau of Standards 1939; 23 (1): 39–61 
(Research Paper RP1220) 
 
Koulourides T, Phantumvanit P, Munksgaard EC, Housch T: An intraoral model used for studies of 
fluoride incorporation in enamel. J Oral Pathol 1974;3:185–196. 
 
Lippert F, Butler A, Lynch RJ: Characteristics of methylcellulose acid gel lesions created in human 
and bovine enamel. Caries Res 2013;47:50–55.  
 
Lippert F, Lynch RJ: Comparison of Knoop and Vickers surface microhardness and transverse 
microradiography for the study of early caries lesion formation in human and bovine enamel. Arch 
Oral Biol 2014;59:704–710. 
 
Lynch RJM, Mony U, ten Cate JM: Effect of lesion characteristics and mineralising solution type on 
enamel remineralisation in vitro. Caries Res 2007;41:257–262. 
 
Lynch RJM, Smith SR: Remineralization agents—new and effective or just marketing hype? Adv 
Dent Res 2012;24:63–67. 
 
Martinez-Mier EA, Cury J, Heilman J, Levy SM, Li Y, Maguire J, Margineda A, O’Mullane D, 
Phantumvanit P, Soto AE, Stookey GK, Villa A, Wefel JS, Whitford GM, Zero DT, Zhang W, 
Zohouri V: Development of standard fluoride analytical methods: Direct analysis. Caries Res 
2004;38:372. Abstract 45. 
 
Martinez-Mier EA, Buckley CB, Chandrappa P, Soto-Rojas AE: Development of a Standard Fluoride 
Analytical Method for Dental Plaque. J Dent Res 2010;89 (Spec Issue):931.  
 
Mellberg JR, Petrou ID, Grote NE: Findings from an in situ thin-section sandwich model for 
evaluating cariogenic and anti-cariogenic activity. J Dent Res 1992;71 Spec No:850–855. 
 
Mukai Y, Lagerweij MD, ten Cate JM: Effect of a solution with high fluoride concentration on 
remineralization of shallow and deep root surface caries in vitro. Caries Res 2001;35:317–324. 
 
Proskin HM, Chilton NW, Kingman A: Interim report of the ad hoc committee for the consideration 
of statistical concerns related to the use of intra-oral models in submissions for product claims 
approval to the American Dental Association. J Dent Res 1992;71(Spec Iss):949–952. 
15 
 
 
Robinson C, Shore RC, Brookes SJ, Strafford S, Wood SR, Kirkham J: The chemistry of enamel 
caries. CROBM 2000;11:481–495. 
 
Sakkab NY, Cilley WA, Haberman JP: Fluoride in deciduous teeth from an anti-caries clinical study. 
J Dent Res 1984;63:1201–1205. 
 
Strang R, Damato FA, Creanor SL, Stephen KW: The effect of baseline lesion mineral loss on in situ 
remineralization. J Dent Res 1987;66:1644–1646. 
 
Taves DR: Separation of fluoride by rapid diffusion using hexamethyldisiloxane. Talanta 
1968;15:969–974. 
 
 
Wefel JS: NovaMin®: likely clinical success. Adv Dent Res 2009;21:40–43. 
 
White DJ: Use of synthetic polymer gels for artificial carious lesion preparation. Caries Res 
1987;21:228–242. 
 
Zero DT: In situ caries models. Adv Dent Res 1995;9:214–230. 
 
Zero DT, Rahbek I, Fu J, Proskin HM, Featherstone JDB: Comparison of the iodide permeability test, 
surface microhardness test and mineral dissolution of bovine enamel following acid challenge. Caries 
Res 1990;24:181–188. 
 
Zero DT, Zhang JZ, Harper DS, Wu M, Kelly S, Waskow J, Hoffman M: The remineralizing effect of 
an essential oil fluoride mouthrinse in an intraoral caries test. J Am Dent Assoc 2004;135:231–237.
 
  
16 
 
Legends 
Figure 1. Trial flow 
 
Figure 2. Mean mineral distribution for baseline lesions (after demineralization) and all post-
treatment groups (after in situ phase). 
 
Table 1. Surface-softened lesions: least square means (SE) and statistical analysis of efficacy 
variables following 21 days’ treatment (PP population, n=75 for all) 
 
Table 2. Subsurface lesions: least square means (SE) and statistical analysis of efficacy variables 
following 28 days’ treatment (PP population, n=75 for all) 
 
Table 3. Summary of treatment-emergent adverse events (TEAEs) (Safety population)  
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Table 1.  
Variable 927 ppm F/5% 
CSPS 
927 ppm F/0% CSPS 250 ppm F/0% 
CSPS 
0 ppm F/5% CSPS 0 ppm F/0% 
CSPS 
SMHR (%) 27.5 (2.19) A 28.5 (2.31) A 18.7 (2.20) B 15.5 (2.30) B 18.0 (2.23) B 
EFU (µg/cm2) 19.8 (0.77) A 19.1 (0.82) A 12.2 (0.78) B 7.4 (0.82) C 7.0 (0.79) C 
ECU (µg/cm2) 8885.7 (193.55)  A 8617.7 (206.01) AB 8387.6 (194.80) B 8369.4 (204.91) B 8363.4 (198.12) B 
Plaque-F (µg/g) 1.7 (0.06) A 1.7 (0.07) A 1.5 (0.06) B 1.4 (0.07) B 1.4 (0.06) B 
Plaque-Ca (µg/g) 2.5 (0.06) A 2.7 (0.06) A 2.5 (0.06) A 2.5 (0.06) A 2.5 (0.06) A 
 
Statistically significant (p<0.0005) within-variable differences highlighted by different letters along rows 
SMHR = surface microhardness recovery; EFU = enamel fluoride uptake; ECU = enamel calcium uptake; CSPS = calcium sodium phosphosilicate
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Table 2. 
Variable 927 ppm F/5% CSPS 927 ppm F/0% CSPS 250 ppm F/0% CSPS 0 ppm F/5% CS      
ΔM (vol%·µm) -474.9 (256.14) A -600.8 (267.46) AB -946.6 (259.36) B -1557.4 (265.33)     
ΔL (µm) 36.4 (7.87) A 39.2 (8.16) AB 49.1 (7.94) BC 56.0 (8.11)     
ΔSZmax (vol%) 8.2 (0.78) A 5.6 (0.84) B 6.5 (0.79) AB 4.7 (0.83)     
EFU (µg/cm2) 42.3 (1.66) A 41.5 (1.78) A 26.0 (1.69) B 13.3 (1.75)     
ECU (µg/cm2) 15,400.6 (344.04) A 14,697.3 (370.81) A 14,899.7 (350.97) AB 14,176.4 (365.72)     
Plaque-F (µg/g) 1.9 (0.07) A 1.7 (0.07) B 1.5 (0.07) BC 1.4 (0.07)     
Plaque-Ca (µg/g) 2.4 (0.06) A 2.5 (0.07) A 2.4 (0.07) A 2.4 (0.07)     
Statistically significant (p<0.05) within-variable differences highlighted by different letters along 
rows 
ΔM = change in mineral content; ΔL = change in lesion depth; ΔSZmax = change in maximum mineral 
density at the surface zone; EFU = enamel fluoride uptake; ECU = enamel calcium uptake; CSPS = 
calcium sodium phosphosilicate 
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Table 3.  
 927 ppm F/5% 
CSPS 
n=69 
927 ppm F/0% 
CSPS 
n=62 
250 ppm F/0% 
CSPS 
n=69 
0 ppm F/5% 
CSPS 
n=62 
0 ppm F/0% 
CSPS 
n=65 
 n (%) nAE n (%) nAE n (%) nAE n (%) nAE n (%) n  
No. subjects with ≥1 TEAE 17 (24.6) 30 9 (14.5) 22 23 (33.3) 27 15 (24.2) 17 14 (21.5)  
Oral TEAE 13 (18.8) 24 3 (4.8) 6 8 (11.6) 9 4 (6.5) 6 5 (7.7)  
Treatment-related TEAE 0 0 0 0 0 0 1 (1.6) 3 2 (3.1)  
Oral mucosal exfoliation 0 0 0 0 0 0 1 (1.6) 1 1 (1.5)  
Stomatitis 0 0 0 0 0 0 1 (1.6) 2 0  
Dysgeusia 0 0 0 0 0 0 0 0 1 (1.5)  
n (%) = number (%) of subjects; nAE = number of AE 


